# A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

Source: https://onco.cc/trials/nct06155084/  
OnCo record `nct06155084` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HP518 - Dose Escalation in prostate cancer, run by Hinova Pharmaceuticals Inc., now recruiting.

## Summary

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients is a phase 1/2 interventional study registered as NCT06155084 by Hinova Pharmaceuticals Inc., with 84 participants planned, started 2023-12-26 and due to reach its primary completion in 2026-03. Interventions recorded: HP518 - Dose Escalation and HP518 -Dose Expansion.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06155084
- Phase: 1/2
- Setting: A Phase I/II Open-Label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer in China
- Sponsor: Hinova Pharmaceuticals Inc.
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT06155084: https://clinicaltrials.gov/study/NCT06155084

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Hinova Pharmaceuticals](https://onco.cc/companies/hinova-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06155084.json